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Background: Diabetic patients have an increased risk of developing cardiovascular diseases, which are the leading
cause of death in developed countries. Although multivitamin products are widely used as dietary supplements, the
effects of these products have not been investigated in the diabetic heart yet. Therefore, here we investigated if a
preparation of different minerals, vitamins, and trace elements (MVT) affects the cardiac gene expression pattern in
experimental diabetes.
Methods: Two-day old male Wistar rats were injected with streptozotocin (i.p. 100 mg/kg) or citrate buffer to
induce diabetes. From weeks 4 to 12, rats were fed with a vehicle or a MVT preparation. Fasting blood glucose
measurement and oral glucose tolerance test were performed at week 12, and then total RNA was isolated from
the myocardium and assayed by rat oligonucleotide microarray for 41012 oligonucleotides.
Results: Significantly elevated fasting blood glucose concentration and impaired glucose tolerance were markedly
improved by MVT-treatment in diabetic rats at week 12. Genes with significantly altered expression due to diabetes
include functional clusters related to cardiac hypertrophy (e.g. caspase recruitment domain family, member 9; cytochrome
P450, family 26, subfamily B, polypeptide; FXYD domain containing ion transport regulator 3), stress response (e.g.
metallothionein 1a; metallothionein 2a; interleukin-6 receptor; heme oxygenase (decycling) 1; and glutathione S-transferase,
theta 3), and hormones associated with insulin resistance (e.g. resistin; FK506 binding protein 5; galanin/GMAP
prepropeptide). Moreover the expression of some other genes with no definite cardiac function was also changed such
as e.g. similar to apolipoprotein L2; brain expressed X-linked 1; prostaglandin b2 synthase (brain). MVT-treatment in diabetic
rats showed opposite gene expression changes in the cases of 19 genes associated with diabetic cardiomyopathy. In
healthy hearts, MVT-treatment resulted in cardiac gene expression changes mostly related to immune response
(e.g. complement factor B; complement component 4a; interferon regulatory factor 7; hepcidin).
Conclusions: MVT-treatment improved diagnostic markers of diabetes. This is the first demonstration that MVT-
treatment significantly alters cardiac gene expression profile in both control and diabetic rats. Our results and further
studies exploring the mechanistic role of individual genes may contribute to the prevention or diagnosis of cardiac
complications in diabetes.
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In 2014, the global prevalence of diabetes mellitus (DM)
was estimated to be 9 % among adults aged over 18 years
[1] reaching epidemic rates in the 21st century [2]. The
number of patients diagnosed with DM is continuously
increasing due to the increasing prevalence of hyperlip-
idaemia, visceral obesity and physical inactivity world-
wide [2–4]. The total number of people suffering from
DM is projected to rise to 552 million in 2030 [5].
Regular consumption of complex preparations con-
taining various vitamins, minerals, and trace elements
(MVT) is common in developed countries [6] to main-
tain general health. In the USA, for instance, more than
half of the adult population use dietary supplements
[7, 8], primarily in the form of multivitamins with or
without minerals [9, 10]. In 1998 a study reported that
in Germany 18 % of men and 25 % of women were regu-
lar consumers of multivitamins among 18–79 years old
adults [11]. Moreover, MVT preparations appeared on
the market as medical food for patients suffering from
metabolic diseases including hyperlipidaemia, metabolic
syndrome, and DM. However, the literature is limited
and controversial on the potential beneficial effects of
these complex preparations containing more than 3
components on disease progression [12–16]. We have
recently shown that chronic treatment with a MVT prep-
aration improved well-established diagnostic markers of
DM such as fasting blood glucose, HbA1c, glucose toler-
ance, and serum insulin levels in male diabetic rats [14].
It is well known that diabetic patients have an in-
creased risk of developing cardiovascular diseases in-
cluding diabetic cardiomyopathy [17]. Cardiovascular
complications are estimated to be responsible for more
than 50 % of deaths among this population [18]. To ex-
plain the development of cardiovascular complications,
the effect of DM on the cardiac gene expression pattern
was investigated in a few studies [19–22]. In addition,
we have previously shown that metabolic syndrome,
which is a precursor state of type 2 DM, alters cardiac
gene expression pattern in male ZDF rats [23]. However,
the effect of MVT preparations on the cardiac gene ex-
pression pattern either in healthy or in diabetic condi-
tion has not yet been investigated.
Therefore, here we aimed at investigating the effects of
a MVT preparation containing 26 different minerals, vi-
tamins and vitamin-like antioxidants, as well as trace el-
ements on the cardiac gene expression pattern in male
diabetic rats.
Materials and methods
Animals
This investigation conforms to the National Institutes of
Health Guide for the Care and Use of Laboratory Ani-
mals (NIH Pub. No. 85–23, Revised 1996) and wasapproved by the Animal Research Ethics Committee of
the University of Szeged.
Two-day old neonatal male Wistar rats were used in
this study. Lactating females with their litters were sep-
arately housed in individually ventilated cages (Sealsafe
IVC system, Italy) and were maintained in a temperature-
controlled room using 12:12 h light:dark cycles for
4 weeks. After separation from the mother at week 4,
males were fed with standard rat chow (Additional file 1)
and housed in pairs under the same circumstances as
mentioned above until 12 weeks of age.
The injection of neonatal rats with streptozotocin
(STZ) is a well characterized and recognized model of
diabetes mellitus [24–27]. This model has been particu-
larly characterized in detail in our previous study [14].
STZ is toxic especially to pancreatic β-cells. In contrast
to injection of STZ to adult rats in a lower dose (60 mg/kg)
that leads to type 1 diabetes with severe hyperglycemia
[14, 24–27], administration of STZ to neonatal rats in a
higher dose (90–100 mg/kg) leads to acute hyperglycemia
within the first few days without resulting in complete
loss of insulin production [14, 24–27]. According to lit-
erature data, after 5–6 weeks, the surviving rats develop
characteristic symptoms of type 2 diabetes mellitus in-
cluding dyslipidemia, hyperglycemia, impaired glucose
tolerance and insulin resistance due to decreased β-cell
mass [14, 24–27]. After 10–12 weeks, cardiovascular
complications including hypertension and LV hyper-
trophy with decreased cardiac function are present in
neonatal STZ-treated rats [28–34]. Therefore, this model
is an appropriate choice to perform anti-diabetic drug
screening studies.
Experimental protocol
Two days old neonatal male Wistar rats were intraperi-
toneally injected with 100 mg/kg of STZ (n = 25) or its
vehicle (ice-cold citrate buffer, n = 16) to induce experi-
mental DM as described earlier [14].
At week 4, fasting blood glucose (FBG) measurement
followed by an oral glucose tolerance test (OGTT) were
performed in order to verify the development of im-
paired glucose tolerance in DM in surviving animals
(data not shown). Mortality rates were 0 % and 36 % in
citrate buffer-treated and in the STZ-treated group, re-
spectively. Both citrate buffer-treated (n = 16) and STZ-
treated rats (n = 16) were then supplemented per os via
gavage (1 mL/kg, 1 % methylcellulose suspension) with a
MVT preparation (253.3 mg/kg/day, suspended in meth-
ylcellulose, n = 8-8) or its vehicle (157 mg/kg/day, sus-
pended in methylcellulose, n = 8-8) for 8 weeks as
described previously [14]. The MVT preparation admin-
istered in the present study is a registered medical food
for human use (Diacomplex film-coated tablet, Béres
Pharmaceuticals, Budapest, Hungary; for content see
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preparation, the daily rat dose was adjusted according to
the ratio of human and rat body surface areas as de-
scribed previously [14]. Body weight was monitored
every week. FBG, haemoglobin A1c level measurement
and OGTT were performed at week 12 to assess the ef-
fect of MVT-treatment on DM. Serum insulin measure-
ments were performed at week 4, 8 and 12 in order to
monitor the insulin secretion of pancreatic beta cells
and the effect of MVT-treatment on the severity of pan-
creatic beta cell damage due to STZ-treatment. At week
12, the rats were anaesthetized using pentobarbital
(Euthasol, i.p. 50 mg/kg; Produlab Pharma b.v., Raams-
donksveer, The Netherlands) [35]. Hearts and pancreata
were isolated, and then the hearts were perfused accord-
ing to Langendorff as described earlier [36, 37]. Coron-
ary flow was measured during the ex vivo perfusion
protocol [35]. After 10 min perfusion, ventricular tissue
was frozen and stored at −80 °C until DNA microarrayTable 1 Ingredients of the MVT preparation
Active ingredients Amount of ingredie
Vitamin A1 (Retinol) 329 μg/g (109700 IU
Vitamin B1 (Thiamin) 2.30 mg/g
Vitamin B2 (Riboflavin) 2.63 mg/g
Vitamin B3 (Nicotinamide) 11.8 mg/g
Vitamin B5 (Pantothenic acid) 3.95 mg/g
Vitamin B6 (Pyridoxine) 3.29 mg/g
Vitamin B12 (Cyanocobalamin) 3 μg/g
Folic acid 197 μg/g
Biotin 99 μg/g
Vitamin D3 (Cholecalciferol) 3 μg/g (120 IU/g)
Vitamin K1 (Phyllokinone) 26 μg/g
Rutoside 3.29 mg/g
Vitamin C 65.8 mg/g
Vitamin E 32.9 mg/g
Lutein 1.97 mg/g
Chrome 39 μg/g
Zinc 9.87 mg/g
Selenium 26 μg/g
Iron 2.63 mg/g
Iodine 66 μg/g
Manganese 0.66 mg/g
Copper 921 μg/g
Molybdenum 49 μg/g
Magnesium 65.8 mg/g
Calcium 132 mg/g
Phosphorus 102 mg/g
aTo conform to the human daily dose of the preparation, rat daily dose was adjusteinvestigation and gene expression analysis could be per-
formed. Pancreata were removed, trimmed free of adi-
pose tissue, then frozen and stored for pancreatic insulin
content determination as described previously [23].
FBG measurements and OGTT
Rats were fasted overnight (12 h) prior to blood glucose
level measurement and OGTT (week 12) in order to ver-
ify the development of DM and to monitor the effect of
MVT-treatment on the progression of DM as described
previously [14]. Briefly, blood samples were collected
from the saphenous vein and blood glucose levels were
measured using Accucheck blood glucose monitoring
systems (Roche Diagnostics Corporation, USA, Indian-
apolis) [14, 23]. After measurement of baseline glucose
concentrations, glucose at 1.5 g/kg body weight was ad-
ministered via oral gavage and plasma glucose levels
were measured 30, 60 and 120 minutes later during
OGTT [14, 23].nt/1 g product Daily dosea
/g) 83.3 μg/kg/day (278 IU/kg/day)
0.58 mg/kg/day
0.67 mg/kg/day
2.99 mg/kg/day
1.00 mg/kg/day
0.83 mg/kg/day
0.76 μg/kg/day
49.9 μg/kg/day
25.1 μg/kg/day
0.76 μg/kg/day (30.4 IU/kg/day)
6.59 μg/kg/day
0.83 mg/kg/day
16.7 mg/kg/day
8.33 mg/kg/day
0.50 mg/kg/day
9.88 μg/kg/day
2.50 mg/kg/day
6.59 μg/kg/day
0.67 mg/kg/day
16.7 μg/kg/day
0.17 mg/kg/day
233 μg/kg/day
12.4 μg/kg/day
16.7 mg/kg/day
33.4 mg/kg/day
25.8 mg/kg/day
d according to the ratio of human and rat body surface areas
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To monitor the effect of the MVT containing prepar-
ation on the severity of DM, haemoglobin A1c was mea-
sured from whole venous blood with an in vitro test
(Bio-Rad in2it System) according to the instructions of
the manufacturer [14]. The test is based on single wave
length photometry (440 nm) to detect glycated fraction
separated from the non-glycated fraction by boronate af-
finity chromatography [14].
Measurement of serum and pancreatic insulin levels
To monitor the effect of MVT-treatment on the sever-
ity of DM, serum and pancreatic insulin levels were
measured by an enzyme immunoassay (Mercodia, Ul-
trasensitive Rat Insulin ELISA) in duplicates according
to the manufacturer’s instructions as described previ-
ously [14, 23].
RNA preparation and DNA microarray analysis
Total RNA was isolated from heart samples with Qiagen
miRNeasy Mini Kit according to the manufacturer’s
protocol (Qiagen, Hilden, Germany). On-column DNase
digestion was carried out with the RNase-Free DNase
Set (Qiagen GmbH). RNA concentration was measured
by NanoDrop 1000 Spectrophotometer (Thermo Fisher
Scientific Inc., Waltham, MA, USA) and RNA integrity
was determined by an Agilent 2100 Bioanalyzer System
(Agilent Technologies Inc., Santa Clara, CA, USA). Sam-
ples with an RNA integrity number (RIN) above 8.0 were
used for further analysis. RNA was stored at −80 °C
until use.
Total RNA (200 ng) was labelled and amplified using
the Low Input Quick Amp Labelling Kit according to
the instructions of the manufacturer. Labelled RNA was
purified and hybridized to Agilent Whole Rat Genome
4x44K array slides, according to the manufacturer’s
protocol. After washing, array scanning and feature ex-
traction was performed with default scenario by Agilent
DNA Microarray Scanner and Feature Extraction Soft-
ware 11.01.
Messenger RNA (mRNA) expression profiling by qRT-PCR
In order to validate gene expression changes obtained by
DNA microarray, qRT-PCR was performed on a Rotor-
Gene 3000 instrument (Corbett Research, Sydney,
Australia) with gene-specific primers and SybrGreen
protocol to monitor gene expression as described earlier
[23]. Briefly, 2 μg of total RNA was reverse transcribed
using the High-Capacity cDNA Archive Kit (Applied
Biosystems Foster City, CA, USA) according to the man-
ufacturer’s instructions in a final volume of 30 μL. After
dilution with 30 μL of water, 1 μL of the diluted reaction
mix was used as a template in the qRT-PCR with Fas-
tStart SYBR Green Master mix (Roche Applied Science,Mannheim, Germany) with the following protocol:
10 min at 95 °C followed by 45 cycles of 95 °C for
15 sec, 60 °C for 25 sec and 72 °C for 25 sec. The fluor-
escence intensity of SybrGreen dye was detected after
each amplification step. Melting temperature analysis
was done after each reaction to check the quality of the
products. Primers were designed using the online Roche
Universal Probe Library Assay Design Center. The qual-
ity of the primers was verified by MS analysis provided
by Bioneer (Daejeon, Korea). Relative expression ratios
were calculated as normalized ratios to rat HPRT and
Cyclophyllin genes. A non-template control sample was
used for each primer to check primer-dimer formation.
The final relative gene expression ratios were calculated
as delta-delta Ct values. Fold change refers to 2-ΔΔCt (in
the case of up-regulated genes) and –(1/2-ΔΔCt) (in the
case of down-regulated genes).
Statistical analysis
Statistical analysis was performed by using Sigmaplot
12.0 for Windows (Systat Software Inc). All values are
presented as mean ± SEM. Two-Way ANOVA was used
to determine the effect of DM or MVT on body weight,
FBG, glucose levels during OGTT, OGTT AUC, HbA1c,
serum and pancreatic insulin concentrations, pancreas
weight and coronary flow. After ANOVA, all pairwise
multiple comparison procedures with Holm-Šídák post
hoc tests were used as multiple range tests. P < 0.05 was
accepted as a statistically significant difference.
In the microarray experiments, biological and tech-
nical replica tests were carried out to gain raw data for
statistical analysis. Altogether 9 individual parallel gene
activity comparisons were done between two groups.
Both in the microarray and qRT-PCR experiments, a
two-sample t-test was used and the p value was deter-
mined to find significant gene expression changes in 3
separate comparisons. In the microarray experiments, a
corrected p value was determined for each gene to control
the false discovery rate using the Benjamini and Hochberg
multiple testing correction protocol. Gene expression ra-
tios with p value of <0.05 and log2 ratio of < −0.85 or log2
ratio of >0.85 (~1.8 fold change) were considered as re-
pression or overexpression respectively in gene activity.
Results
Characterization of experimental DM and the effects of
MVT-treatment on the progression of DM
The time dependence of development of DM in neonatal
STZ-treated rats in both genders has been particularly
characterized in detail in our previous study [14]. In the
present study, concentrations of several plasma metabo-
lites and body weight were measured in order to verify
the development of DM in the STZ-treated rats (Fig. 1).
OGTT showed increased glucose levels at every time
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Fig. 1 Characterization of experimental DM and the effects of MVT-treatment on the progression of DM. a Blood glucose levels during oral glucose
tolerance test (OGTT) and b its area under the curve (AUC). c Level of fasting blood glucose and d haemoglobin A1c. e Serum and f pancreas
insulin. g Body and h pancreas weight. Values are expressed as mean ± S.E.M. *p < 0.05 vs. control, #p < 0.05 vs. diabetes vehicle, two-way ANOVA,
n = 8 in each group. Cont = Control, Diab = Diabetes, Veh = Vehicle, MVT = preparation of minerals, vitamins, and trace elements
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creased area under the curve (AUC) values in STZ-
treated groups showing impaired glucose tolerance
(Fig. 1a and b). MVT-treatment significantly decreased
glucose and OGTT AUC values in the STZ-treated
groups, proving an anti-diabetic effect of the MVT prep-
aration (Fig. 1a and b). FBG level was significantly higher
in STZ-treated groups as compared to the control groupshowing the development of DM (Fig. 1c). However,
FBG level was significantly decreased by MVT-treatment
in the STZ-treated diabetic group (Fig. 1c). HbA1c level
was significantly increased in STZ-treated groups as
compared to controls (Fig. 1d) demonstrating chronic
hyperglycaemia and the development of DM. Interest-
ingly, MVT-treatment significantly reduced the HbA1c
level in the STZ-treated diabetic group (Fig. 1d). Serum
Table 2 Genes significantly down-regulated in diabetes vehicle-treated vs. control vehicle-treated group on DNA microarray
Diabetes Vehicle Diabetes MVT Control MVT
vs. vs. vs.
Control Vehicle Diabetes Vehicle Control Vehicle
Gene function Gene Name provided by RGDa Acc. Number Gene Symbol Log2 (SD) Corr. p Fold change Log2 (SD) Fold Change Log2 (SD) Fold Change
Metabolism UDP-Gal:betaGlcNAc beta
1,3-galactosyltransferase, polypeptide 2
NM_001109492 B3galt2 -1.14 (0.19) 0.003 -2.21 0.80 (0.49) 1.74 -0.16 (0.60) -1.11
Metabolism adenylate kinase 4 NM_017135 Ak4 -0.99 (0.49) 0.026 -1.99 0.76 (0.40) 1.70 -0.47 (0.70) -1.38
Stress response APEX (apurinic/apyrimidinic)
endonuclease 2
NM_001079892 Apex2 -0.94 (0.56) 0.042 -1.92 0.09 (0.26) 1.06 -1.18 (0.63) -2.26
Apoptosis/necrosis and inflammation caspase recruitment domain family,
member 9
NM_022303 Card9 -2.74 (0.64) 0.003 -6.69 1.82 (0.52) 3.53 -1.20b (0.88) -2.29
Apoptosis/necrosis and inflammation chemokine (C-X-C motif) ligand 12 NM_001033883 Cxcl12 -0.86 (0.38) 0.021 -1.82 0.48 (0.40) 1.40 0.06 (0.30) 1.04
Cell growth and differentiation neuronal regeneration related protein NM_178096 Nrep -1.11 (0.55) 0.023 -2.46 0.50 (0.49) 1.41 -1.46b (1.36) -2.74
Cell growth and differentiation HOP homeobox NM_133621 Hopx -1.14 (0.52) 0.020 -2.20 0.60 (0.49) 1.51 -0.28 (0.71) -1.21
Cell growth and differentiation fibroblast growth factor 18 NM_019199 Fgf18 -1.12 (0.53) 0.021 -2.17 0.80 (0.57) 1.74 -0.51 (0.23) -1.43
Cell growth and differentiation ret proto-oncogene NM_012643 Ret -1.04 (0.14) 0.003 -2.06 0.63 (0.39) 1.55 -0.63 (0.15) -1.55
Cell growth and differentiation G0/G1 switch 2 NM_001009632 G0s2 -0.86 (0.21) 0.007 -1.82 0.58 (0.47) 1.50 0.26 (0.91) 1.20
Receptors and ion channels adrenoceptor alpha 1D NM_024483 Adra1d -1.21 (0.52) 0.016 -2.31 1.12 (0.40) 2.17 -1.03b (1.36) -2.04
Receptors and ion channels FXYD domain-containing ion transport
regulator 3
NM_172317 Fxyd3 -1.01 (0.49) 0.023 -2.01 1.97 (0.48) 3.92 -0.36 (0.85) -1.29
Receptors and ion channels sodium channel, voltage-gated,
type IV, beta
NM_001008880 Scn4b -0.94 (0.30) 0.011 -1.92 0.38 (0.15) 1.30 -0.43 (0.49) -1.35
Receptors and ion channels transferrin receptor NM_022712 Tfrc -0.87 (0.21) 0.007 -1.83 0.09 (0.20) 1.06 -0.55 (0.32) -1.46
Structural protein, cell adhesion myosin binding protein C, fast-type NM_001106257 Mybpc2 -0.93 (0.47) 0.026 -1.90 0.33 (0.52) 1.25 0.48 (0.82) 1.40
Structural protein, cell adhesion protocadherin 17 NM_001107279 Pcdh17 -0.94 (0.44) 0.023 -1.91 0.90 (0.43) 1.86 -0.65 (0.43) -1.57
Hormones inhibin alpha NM_012590 Inha -0.89 (0.39) 0.020 -1.85 1.59 (0.79) 3.01 0.66 (0.21) 1.58
Transport globin, alpha NM_001013853 LOC287167 -1.64 (0.72) 0.015 -3.12 -0.23 (0.81) -1.18 -1.80 (0.76) -3.47
Transport haemoglobin, beta adult major chain NM_198776 Hbb-b1 -1.94 (0.75) 0.011 -3.83 -0.40 (0.77) -1.32 -2.23 (0.76) -4.71
Transport alpha-2u globulin PGCL5 NM_147213 LOC259245 -0.87 (0.54) 0.047 -1.83 -0.03 (0.48) -1.02 -0.12 (0.58) -1.08
Others uncharacterized LOC100909684 XR_146107 LOC10099684 -3.07 (1.43) 0.016 -8.43 2.55 (1.40) 5.85 -0.42 (0.76) -1.34
Others uncharacterized LOC100910110 XR_146304 LOC100910110 -1.94 (0.32) 0.003 -3.85 2.32 (0.31) 5.01 -0.46 (1.57) -1.38
Values show gene expression. Log2 ratio reaching at least ±0.85 and p < 0.05 were considered as significant alterations
aRGD: rat genome database
bnon significant change (p > 0.05)
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injected vehicle-treated group as compared to control
vehicle-treated group both at week 4 (0.05 ± 0.01 vs.
0.16 ± 0.02 μg/mL) and 8 (0.08 ± 0.02 vs. 0.17 ± 0.02 μg/
mL) proving deteriorated pancreatic beta cell function in
DM. MVT-treatment had no significant effect on serum
insulin levels at weeks 4 and 8 in diabetic (0.06 ± 0.01
and 0.12 ± 0.03 μg/mL, respectively) and control animals
(0.12 ± 0.02 and 0.25 ± 0.03 μg/mL) when compared to
appropriate vehicle-treated controls. At week 12, serum
and pancreatic insulin concentration were significantly
decreased in STZ-treated diabetic animals, proving pan-
creatic β-cell damage (Fig. 1e and f). MVT-treatment
showed a significant increase in serum insulin concen-
trations in STZ-treated animals (Fig. 1e). However,
MVT-treatment failed to significantly improve pancre-
atic insulin content in STZ-treated diabetic animals
(Fig. 1f ). In addition, body weight gain of STZ-treated
rats was significantly lower as compared to control
rats. However, weight gain was significantly improved
by the MVT-treatment in the STZ-treated group
(Fig. 1g). Neither DM nor MVT-treatment had a sig-
nificant effect on pancreas weight (Fig. 1h). Coronary
flow was significantly lower in the diabetic vehicle-
treated group as compared to the control vehicle-
treated group (16.4 ± 2.04 vs. 19.25 ± 0.48 mL/min)
showing impaired cardiac function in diabetic hearts.
However, MVT-treatment failed to improve coronary
flow in the diabetic group (17.0 ± 0.52 mL/min) and
had no significant effect in the control group either
(19.29 ± 0.94 mL/min).Global cardiac gene expression changes
To determine genes in 1) diabetic vehicle-treated, 2) dia-
betic MVT-treated, 3) control vehicle-treated and 4) con-
trol MVT-treated groups, total RNA isolation and then
DNA microarray analysis were performed from the hearts
of all groups. Among the 41012 rat oligonucleotides sur-
veyed, 16752 oligonucleotides in diabetic vehicle-treated
group, 17531 oligonucleotides in diabetic MVT-treated
group, 17447 oligonucleotides in control vehicle-
treated group and 17184 oligonucleotides in control
MVT-treated group showed expression.Identification of genes associated with DM
To determine genes associated with DM and diabetic
cardiomyopathy, cardiac gene expression induced in the
diabetic vehicle-treated group was compared with the
control vehicle-treated group (Tables 2 and 3). In dia-
betic vehicle-treated hearts, 37 genes showed significant
up-regulation and 22 genes showed significant down-
regulation (Tables 2 and 3).Identification of genes associated with MVT-treatment in
DM
To determine genes associated with the effects of MVT-
treatment in diabetic hearts, cardiac gene expression in-
duced in the diabetic MVT-treated group was compared
with the diabetic vehicle-treated group (Tables 4 and 5).
In diabetic MVT-treated hearts, 15 genes showed signifi-
cant up-regulation and 29 genes showed significant
down-regulation, compared to diabetic vehicle-treated
controls (Tables 4 and 5). In the diabetic MVT-treated
group, an additional 23 genes were found, which expres-
sion pattern was significantly influenced only by the
MVT-treatment. These 23 genes did not show signifi-
cant gene expression change in the diabetic vehicle-
treated group as compared to the control vehicle-treated
group (Tables 2 and 5). To assess potential beneficial ef-
fects of MVT-treatment, we analysed opposite gene ex-
pression changes in the diabetic MVT-treated group as
compared to the diabetic vehicle-treated group. Among
the oppositely altered genes in the diabetic MVT-treated
group, 5 genes showed significant up-regulation and 14
genes showed significant down-regulation, respectively
(Fig. 2). These 19 genes may be associated with potential
cardioprotective effects of MVT-treatment in DM.
Identification of genes associated with MVT-treatment in
healthy condition
To determine genes associated with the effects of MVT-
treatment in healthy control hearts, cardiac gene expres-
sion induced in the control MVT-treated group was
compared with the control vehicle-treated group (Tables 6
and 7). In control MVT-treated hearts, 18 genes showed
significant up-regulation and 6 genes showed significant
down-regulation (Tables 6 and 7). Out of these signifi-
cantly altered 24 genes, 18 genes were not significantly al-
tered in diabetic MVT-treated rats. These 18 genes may
be associated with potential beneficial effects of MVT-
treatment in healthy or diseased conditions.
Validation of microarray data by qRT-PCR
To confirm the microarray data we measured the ex-
pression of selected 5 genes by qRT-PCR in 2 different
setups: 1) diabetes vehicle-treatment vs. control vehicle-
treatment groups and 2) diabetes MVT-treatment vs.
diabetes vehicle-treatment groups (Tables 8 and 9). In
both setups, the expression changes of 4 genes were
confirmed by qRT-PCR and showed reliability of the
microarray data.
Discussion
In the present study we have confirmed that chronic
treatment with a MVT preparation attenuated the pro-
gression of DM by improving diagnostic markers of DM
including glucose tolerance, FBG, HbA1c, and serum
Table 3 Genes significantly up-regulated in diabetes vehicle-treated vs. control vehicle-treated group on DNA microarray
Diabetes Vehicle Diabetes MVT Control MVT
vs. vs. vs.
Control Vehicle Diabetes Vehicle Control Vehicle
Gene function Gene Name provided by RGDa Acc. Number Gene Symbol Log2 (SD) Corr. p Fold change Log2 (SD) Fold Change Log2 (SD) Fold Change
Metabolism UDP-N-acetyl-alpha-D-galactosamine:
polypeptide
N-acetylgalactosaminyltransferase 15
XM_003752864 Galnt15 0.85 (0.53) 0.047 1.81 −0.58 (0.40) −1.49 0.32 (0.55) 1.25
Metabolism microtubule associated
monooxygenase, calponin and
LIM domain containing 1
NM_001106397 Mical1 0.89 (0.23) 0.007 1.86 −0.21 (0.19) −1.16 0.52 (0.23) 1.43
Metabolism proline dehydrogenase
(oxidase) 1
NM_001135778 Prodh 0.95 (0.48) 0.026 1.93 −0.27 (0.63) −1.21 0.93 (0.50) 1.91
Metabolism 4-hydroxyphenylpyruvate dioxygenase NM_017233 Hpd 1.07 (0.38) 0.011 2.09 −0.06 (0.34) −1.04 1.00 (0.48) 2.01
Stress response glutathione S-transferase, theta 3 NM_001137643 Gstt3 0.88 (0.52) 0.042 1.84 −0.13 (0.38) −1.09 0.61 (0.80) 1.52
Stress response heme oxygenase (decycling) 1 NM_012580 Hmox1 1.08 (0.47) 0.017 2.12 −0.62 (0.49) −1.54 0.52 (0.25) 1.43
Stress response metallothionein 1a NM_138826 Mt1a 1.32 (0.34) 0.005 2.49 −1.18 (0.43) −2.26 0.09 (0.39) 1.06
Stress response metallothionein 2a NM_001137564 Mt2a 1.61 (0.34) 0.003 3.06 −1.70 (0.66) −3.24 0.24 (0.53) 1.18
Immune response NLR family member X1 NM_001025010 Nlrx1 0.87 (0.48) 0.036 1.83 −1.07 (0.43) −2.10 0.30 (0.43) 1.23
Immune response FK506 binding protein 5 NM_001012174 Fkbp5 1.13 (0.52) 0.020 2.19 −1.09 (0.32) −2.13 0.83 (0.74) 1.77
Immune response influenza virus NS1A binding protein NM_001047085 Ivns1abp 1.27 (0.40) 0.008 2.41 −0.65 (0.35) −1.57 0.68 (0.79) 1.60
Apoptosis/necrosis and inflammation interleukin 6 receptor NM_017020 Il6r 0.91 (0.50) 0.034 1.88 −1.00 (0.47) −2.00 0.63 (0.67) 1.54
Cell growth and differentiation H19, imprinted maternally
expressed transcript
NR_027324 H19 0.92 (0.49) 0.032 1.89 −0.53 (0.47) −1.44 1.16 (0.44) 2.24
Cell growth and differentiation secreted frizzled-related protein 2 NM_001100700 Sfrp2 1.22 (0.73) 0.039 2.34 −0.62 (0.77) −1.54 0.87b (0.73) 1.83
Cell growth and differentiation wingless-type MMTV integration
site family, member 2B
NM_001191848 Wnt2b 1.32 (0.11) 0.003 2.50 −1.66 (0.48) −3.15 0.16 (0.11) 1.11
Cell growth and differentiation brain expressed, X-linked 1 NM_001037365 Bex1 1.41 (0.30) 0.003 2.65 −1.97 (0.45) −3.92 0.25 (0.81) 1.19
Cell growth and differentiation N-myc downstream regulated 1 NM_001011991 Ndrg1 0.85 (0.42) 0.027 1.81 −1.05 (0.33) −2.07 0.41 (0.62) 1.33
Receptors and ion channels solute carrier family 26 (anion
exchanger), member 3
NM_053755 Slc26a3 0.88 (0.34) 0.015 1.84 −0.03 (0.23) −1.02 0.01 (0.32) 1.01
Receptors and ion channels ATPase, H+ transporting, lysosomal
V1 subunit G2
NM_212490 Atp6v1g2 0.92 (0.41) 0.020 1.89 −1.05 (0.43) −2.06 −0.75 (0.22) −1.68
Receptors and ion channels ATP-binding cassette, subfamily A
(ABC1), member 1
NM_178095 Abca1 1.01 (0.35) 0.011 2.01 −0.22 (0.39) −1.17 0.54 (0.40) 1.45
Receptors and ion channels sarcolipin NM_001013247 Sln 1.07 (0.61) 0.036 2.10 −0.23 (0.42) −1.17 1.09 (0.61) 2.13
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Table 3 Genes significantly up-regulated in diabetes vehicle-treated vs. control vehicle-treated group on DNA microarray (Continued)
Signal transduction, regulation of
transcription
zinc finger and BTB domain
containing 16
NM_001013181 Zbtb16 0.89 (0.29) 0.011 1.85 −0.69 (0.33) −1.62 0.37 (0.52) 1.30
Signal transduction, regulation of transcription Rho-related BTB domain
containing 1
NM_001107622 Rhobtb1 0.91 (0.25) 0.008 1.88 −0.22 (0.25) −1.16 0.58 (0.55) 1.49
Signal transduction, regulation of transcription connector enhancer of kinase
suppressor of Ras 1
NM_001039011 Cnksr1 1.31 (0.67) 0.025 2.48 −1.64 (0.38) −3.13 0.39 (0.72) 1.31
Signal transduction, regulation
of transcription
cytochrome P450, family 26,
subfamily b, polypeptide 1
NM_181087 Cyp26b1 1.62 (0.28) 0.003 3.08 −1.68 (0.47) −3.20 0.25 (0.30) 1.19
Structural protein, cell adhesion pannexin 2 NM_199409 Panx2 0.97 (0.17) 0.003 1.96 −0.56 (0.33) −1.47 0.81 (0.15) 1.75
Structural protein, cell adhesion myosin light chain kinase 2 NM_057209 Mylk2 1.17 (0.32) 0.006 2.25 −0.05 (0.37) −1.03 1.05b (0.69) 2.08
Hormones resistin NM_144741 Retn 1.08 (0.60) 0.034 2.12 −1.03 (0.44) −2.05 0.51 (0.96) 1.43
Hormones galanin/GMAP prepropeptide NM_033237 Gal 2.41 (1.15) 0.018 5.31 −2.99 (0.92) −7.96 1.82b (1.20) 3.53
Hormones natriuretic peptide A NM_012612 Nppa 1.23 (0.45) 0.011 2.34 −0.62 (0.42) −1.54 0.79 (0.38) 1.73
Others myosin binding protein H-like NM_001014042 Mybphl 1.26 (0.75) 0.038 2.39 −0.66 (0.68) −1.58 1.09b (0.71) 2.13
Others prostaglandin D2 synthase (brain) NM_013015 Ptgds 1.32 (0.69) 0.026 2.50 −0.64 (0.46) −1.56 0.67 (0.87) 1.59
Others visinin-like 1 NM_012686 Vsnl1 1.49 (0.79) 0.026 2.80 −1.01b (0.77) −2.01 1.16b (0.76) 2.24
Others transmembrane protein 140 NM_001009709 Tmem140 1.49 (0.27) 0.003 2.80 −0.59 (0.42) −1.50 0.30 (0.26) 1.23
Others IQ motif and ubiquitin domain
containing
NM_001034130 Iqub 0.94 (0.36) 0.014 1.91 0.23 (0.20) 42021 0.52 (0.59) 1.44
Others similar to apolipoprotein L2;
apolipoprotein L-II
NM_001134801 RGD1309808 4.33 (2.91) 0.049 42358 −6.07 (0.68) −67.24 1.61b (3.76) 3.05
Others thioredoxin domain
containing 16
XM_001072487 Txndc16 0.85 (0.31) 0.015 1.80 −0.72 (0.32) −1.65 0.51 (0.32) 1.42
Values show gene expression. Log2 ratio reaching at least ±0.85 and p < 0.05 were considered as significant alterations
aRGD: rat genome database
bnon significant change (p > 0.05)
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Table 4 Genes significantly down-regulated in diabetes MVT-treated vs. diabetes vehicle-treated group on DNA microarray
Diabetes MVT Diabetes Vehicle Control MVT
vs. vs. vs.
Diabetes Vehicle Control Vehicle Control Vehicle
Gene function Gene Name provided by RGDa Acc. Number Gene Symbol Log2 (SD) Corr. p Fold change Log2 (SD) Fold Change Log2 (SD) Fold Change
Metabolism dipeptidase 1 (renal) L07315 Dpep1 −1.02 (0.27) 0.007 −2.03 0.79 (0.47) 1.72 −0.17 (0.50) −1.12
Metabolism glycosylphosphatidylinositol
anchored high density
lipoprotein binding protein 1
NM_001130547 Gpihbp1 −0.89 (0.18) 0.006 −1.86 0.59 (0.33) 1.50 0.10 (0.37) 1.07
Metabolism flavin containing monooxygenase 2 NM_144737 Fmo2 −0.85 (0.36) 0.028 −1.80 0.80 (0.24) 1.74 0.12 (0.29) 1.08
Stress response metallothionein 2a NM_001137564 Mt2a −1.70 (0.66) 0.018 −3.24 1.61 (0.34) 3.06 0.24 (0.53) 1.18
Stress response metallothionein 1a NM_138826 Mt1a −1.18 (0.43) 0.017 −2.26 1.32 (0.34) 2.49 0.09 (0.39) 1.06
Immune response FK506 binding protein 5 NM_001012174 Fkbp5 −1.09 (0.32) 0.008 −2.13 1.13 (0.52) 2.19 0.83 (0.74) 1.77
Immune response NLR family member X1 NM_001025010 Nlrx1 −1.07 (0.43) 0.023 −2.10 0.87 (0.48) 1.83 0.30 (0.43) 1.23
Apoptosis/necrosis and inflammation chemokine (C-X-C motif) ligand 13 NM_001017496 Cxcl13 −1.66 (0.84) 0.036 −3.17 0.61 (1.02) 1.53 0.18 (0.96) 1.14
Apoptosis/necrosis and inflammation interleukin 6 receptor NM_017020 Il6r −1.00 (0.47) 0.033 −2.00 0.91 (0.50) 1.88 0.63 (0.67) 1.54
Cell growth and differentiation brain expressed, X-linked 1 NM_001037365 Bex1 −1.97 (0.45) 0.004 −3.92 1.41 (0.30) 2.65 0.25 (0.81) 1.19
Cell growth and differentiation wingless-type MMTV
integrationsite family, member 2B
NM_001191848 Wnt2b −1.66 (0.48) 0.007 −3.15 1.32 (0.11) 2.50 0.16 (0.11) 1.11
Cell growth and differentiation RAB3 GTPase activating protein
subunit 2
AI072072 Rab3gap2 −1.25 (0.57) 0.029 −2.38 0.53 (0.33) 1.45 0.22 (0.53) 1.17
Cell growth and differentiation N-myc downstream regulated 1 NM_001011991 Ndrg1 −1.05 (0.33) 0.012 −2.07 0.85 (0.42) 1.81 0.41 (0.62) 1.33
Cell growth and differentiation WNT1 inducible signaling pathway
protein 2
NM_031590 Wisp2 −1.02 (0.53) 0.043 −2.02 0.60 (0.40) 1.52 0.47 (0.34) 1.39
Cell growth and differentiation serine (or cysteine) peptidase
inhibitor, clade A, member 3 N
NM_031531 Serpina3n −0.90 (0.48) 0.048 −1.87 −0.03 (0.39) −1.02 0.90 (1.09) 1.87
Receptors and ion channels ATPase, H+ transporting,lysosomal
V1 subunit G2
NM_212490 Atp6v1g2 −1.05 (0.43) 0.024 −2.06 0.92 (0.41) 1.89 −0.75 (0.22) −1.68
Receptors and ion channels melanocortin 2 receptoraccessory
protein
NM_001135834 Mrap −0.92 (0.42) 0.033 −1.89 0.65 (0.19) 1.56 0.12 (0.21) 1.09
Signal transduction, regulation
of transcription
cytochrome P450, family 26,
subfamily b, polypeptide 1
NM_181087 Cyp26b1 −1.68 (0.47) 0.007 −3.20 1.62 (0.28) 3.08 0.25 (0.30) 1.19
Signal transduction, regulation
of transcription
connector enhancer of kinase
suppressor of Ras 1
NM_001039011 Cnksr1 −1.64 (0.38) 0.004 −3.13 1.31 (0.67) 2.48 0.39 (0.72) 1.31
Structural protein, cell adhesion solute carrier family 43 (amino acid
system L transporter), member 2
NM_001105812 Slc43a2 −1.06 (0.39) 0.019 −2.09 0.34 (0.19) 1.27 −0.07 (0.18) −1.05
Hormones galanin/GMAP prepropeptide NM_033237 Gal −2.99 (0.92) 0.007 −7.96 2.41 (1.15) 5.31 1.82 (1.20) 3.53
Sárközy
et
al.Cardiovascular
D
iabetology
 (2015) 14:85 
Page
10
of
20
Table 4 Genes significantly down-regulated in diabetes MVT-treated vs. diabetes vehicle-treated group on DNA microarray (Continued)
Hormones resistin NM_144741 Retn −1.03 (0.44) 0.025 −2.05 1.08 (0.60) 2.12 0.51 (0.96) 1.43
Others similar to apolipoprotein L2;
apolipoprotein L-II
NM_001134801 RGD1309808 −6.07 (0.68) <0.001 −67.24 4.33 (2.91) 20.12 1.61 (3.76) 3.05
Others secreted phosphoprotein 1 NM_012881 Spp1 −1.35 (0.59) 0.025 −2.55 −0.40 (0.77) −1.32 2.30 (1.49) 4.93
Others elongation of very long chain fatty
acids protein 6-like
XM_003749393 LOC100910695 −1.01 (0.39) 0.021 −2.02 0.33 (0.43) 1.25 −0.94 (0.55) −1.92
Others WW domain binding protein 5 NM_001127502 Wbp5 −0.99 (0.20) 0.005 −1.99 0.54 (0.15) 1.45 0.07 (0.38) 1.05
Others coiled-coil domain containing 136 XM_001064000 Ccdc136 −0.98 (0.10) 0.002 −1.98 0.62 (0.18) 1.53 0.09 (0.39) 1.06
Others multimerin 1 XM_001071128 Mmrn1 −0.91 (0.38) 0.027 −1.88 −0.31 (0.36) −1.24 −0.14 (0.31) −1.10
Others epsin 3 NM_001024791 Epn3 −0.87 (0.44) 0.043 −1.82 0.46 (0.50) 1.37 −0.16 (0.32) −1.12
Values show gene expression. Log2 ratio reaching at least ±0.85 and p < 0.05 were considered as significant alterations
aRGD: rat genome database
bnon significant change (p > 0.05)
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Table 5 Genes significantly up-regulated in diabetes MVT-treated vs. diabetes vehicle-treated group on DNA microarray
Diabetes MVT Diabetes Vehicle Control MVT
vs. vs. vs.
Diabetes Vehicle Control Vehicle Control Vehicle
Gene function Gene Name provided by RGDa Acc. Number Gene Symbol Log2 (SD) Corr. p Fold change Log2 (SD) Fold Change Log2 (SD) Fold Change
Metabolism L-2-hydroxyglutarate
dehydrogenase
NM_001108028 L2hgdh 1.06 (0.49) 0.032 2.09 −0.52 (1.01) −1.44 0.04 (0.92) 1.03
Apoptosis/necrosis and
inflammation
chemokine (C-X-C motif)
ligand 9
NM_145672 Cxcl9 1.03 (0.40) 0.021 2.04 −0.29 (0.60) −1.22 −0.19 (0.81) −1.14
Apoptosis/necrosis and
inflammation
caspase recruitment
domain family, member 9
NM_022303 Card9 1.82 (0.52) 0.007 3.53 −2.74 (0.64) −6.69 −1.20b (0.88) −2.29
Receptors and ion
channels
adrenoceptor alpha 1D NM_024483 Adra1d 1.12 (0.40) 0.017 2.17 −1.21 (0.52) −2.31 −1.03b (1.36) −2.04
Receptors and ion
chanells
FXYD domain-containing
ion transport regulator 3
NM_172317 Fxyd3 1.97 (0.48) 0.004 3.92 −1.01 (0.49) −2.01 −0.36 (0.85) −1.29
Signal transduction, regulation
of transcription
regulator of telomere
elongation helicase 1
NM_001191857 Rtel1 1.14 (0.27) 0.006 2.20 −0.71 (1.02) −1.64 0.58 (1.14) 1.49
Signal transduction,
regulation of transcription
staufen double-stranded
RNA binding protein 2
NM_001007149 Stau2 1.36 (0.71) 0.042 2.56 −0.38 (0.27) −1.30 0.22 (0.41) 1.16
Structural protein, cell
adhesion
protocadherin 17 NM_001107279 Pcdh17 0.90 (0.43) 0.036 1.86 −0.94 (0.44) −1.91 −0.65 (0.43) −1.57
Hormones inhibin alpha NM_012590 Inha 1.59 (0.79) 0.035 3.01 −0.89 (0.39) −1.85 0.66 (0.21) 1.58
Others similar to HTGN29 protein;
keratinocytes associated
transmembrane protein 2
NM_001106999 RGD131352 1.05 (0.48) 0.032 2.07 0.29 (0.49) 1.23 0.49 (0.53) 1.41
Others WDNM1 homolog NM_001003706 LOC360228 1.32 (0.63) 0.033 2.50 −0.59 (0.77) −1.50 1.01b (0.67) 2.01
Others ring finger protein 135 NM_001012010 Rnf135 0.86 (0.33) 0.023 1.82 −0.44 (0.08) −1.35 −0.06 (0.46) −1.05
Others uncharacterized LOC100910110 XR_146304 LOC100910110 2.32 (0.31) 0.001 5.01 −1.94 (0.32) −3.85 −0.46 (1.57) −1.38
Others uncharacterized LOC100909684 XR_146107 LOC10099684 2.55 (1.40) 0.045 5.85 −3.07 (1.43) −8.43 −0.42 (0.76) −1.34
Others serine hydrolase-like 2 NM_001130579 Serhl2 5.17 (0.48) <0.001 35.96 −3.62b (2.81) −12.31 −3.45b (2.82) −10.92
Values show gene expression. Log2 ratio reaching at least ±0.85 and p < 0.05 were considered as significant alterations
aRGD: rat genome database
bnon significant change (p > 0.05)
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Fig. 2 Genes with significantly and oppositely altered expression in diabetes vehicle-treated vs. diabetes MVT-treated group. a Significantly down-regulated
genes in diabetes vehicle-treated group vs. control vehicle-treated group which are up-regulated in diabetes MVT-treated group vs. diabetes vehicle
treated-group. No significant change in control MVT-treated group vs. control vehicle-treated group. b Significantly up-regulated genes in diabetes
vehicle-treated group vs. control vehicle-treated group which are down-regulated in diabetes MVT-treated group vs. diabetes vehicle-treated group.
No significant change in control MVT-treated group vs. control vehicle-treated group. Values are expressed as mean ± S.E.M. Log2 ratio reaching at least
±0.85 (represented with dotted lines) and p < 0.05 were considered as significant alterations
Sárközy et al. Cardiovascular Diabetology  (2015) 14:85 Page 13 of 20insulin levels in male diabetic rats [14]. We have shown
here that the development of DM induces marked alter-
ations in the cardiac gene expression pattern. This is the
first demonstration that a MVT preparation significantly
altered the myocardial [38, 39] gene expression pattern
by altering transcript levels of several genes in both dia-
betic and healthy rats. The significantly altered genes
can be classified into different clusters (e.g. metabolism;
stress response; immune response; cell growth anddifferentiation; ion channels and receptors; signal trans-
duction and regulation of transcription; structural pro-
teins and cell adhesion; hormones; transport; etc.). Some
of these genes are related to the development of diabetic
cardiomyopathy (e.g. cardiac hypertrophy and fibrosis,
stress response, hormones associated with insulin resist-
ance, etc.). Moreover, some other genes without any def-
inite function in the myocardium were also changed in
response to DM or MVT-treatment.
Table 6 Genes significantly down-regulated in control MVT-treated vs. control vehicle-treated group on DNA microarray
Control MVT Diabetes Vehicle Diabetes MVT
vs. vs. vs.
Control Vehicle Control Vehicle Diabetes Vehicle
Gene function Gene Name provided by RGDa Acc. Number Gene Symbol Log2 (SD) Corr. p Fold change Log2 (SD) Fold Change Log2 (SD) Fold Change
Stress response APEX (apurinic/apyrimidinic)
endonuclease) 2
NM_001079892 Apex2 −1.18 (0.63) 0.043 −2.26 −0.94 (0.56) −1.92 0.09 (0.26) 1.06
Receptors and ion channels sodium leak channel, non-selective NM_153630 Nalcn −0.85 (0.44) 0.043 −1.80 −0.59 (0.36) −1.50 0.16 (0.41) 1.12
Signal transduction,
regulation of transcription
triggering receptor expressed on
myeloid cells 2
NM_001106884 Trem2 −1.03 (0.40) 0.021 −2.05 −0.21 (0.88) −1.15 −0.98 (0.94) −1.98
Transport hemoglobin, beta adult
major chain
NM_198776 Hbb-b1 −2.23 (0.76) 0.016 −4.71 −1.94 (0.75) −3.83 −0.40 (0.77) −1.32
Transport globin, alpha NM_001013853 LOC287167 −1.80 (0.76) 0.020 −3.47 −1.64 (0.72) −3.12 −0.23 (0.81) −1.18
Others EF-hand calcium binding
domain 6
XM_001077962 Efcab6 −1.66 (0.62) 0.017 −3.15 0.40 (0.99) 1.32 −1.36b (1.38) −2.57
Values show gene expression. Log2 ratio reaching at least ±0.85 and p < 0.05 were considered as significant alterations
aRGD: rat genome database
bnon significant change (p > 0.05)
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Table 7 Genes significantly up-regulated in control MVT-treated vs. control vehicle-treated group on DNA microarray
Control MVT Diabetes Vehicle Diabetes MVT
vs. vs. vs.
Control Vehicle Control Vehicle Diabetes Vehicle
Gene function Gene Name provided by RGDa Acc. Number Gene Symbol Log2 (SD) Corr. p Fold change Log2 (SD) Fold Change Log2 (SD) Fold Change
Metabolism proline dehydrogenase (oxidase) 1 NM_001135778 Prodh 0.93 (0.50) 0.043 1.91 0.95 (0.48) 1.93 −0.27 (0.63) −1.21
Metabolism enolase 2, gamma, neuronal NM_139325 Eno2 1.00 (0.30) 0.017 2.00 0.98b (0.85) 1.97 −1.32b (1.12) −2.50
Metabolism 4-hydroxyphenylpyruvate dioxygenase NM_017233 Hpd 1.00 (0.48) 0.034 2.01 1.07 (0.38) 2.09 −0.06 (0.34) −1.04
Immune response complement factor B NM_212466 Cfb 0.85 (0.32) 0.025 1.80 0.14 (0.34) 1.10 0.22 (0.34) 1.17
Immune response 2’-5’ oligoadenylate synthetase 1A NM_138913 Oas1a 0.92 (0.33) 0.020 1.90 0.40 (0.28) 1.32 −0.43 (0.24) −1.35
Immune response 2-5 oligoadenylate synthetase 1B AF068268 Oas1b 1.04 (0.18) 0.015 2.06 −0.52 (0.50) −1.44 0.11 (0.83) 1.08
Immune response 2’-5’ oligoadenylate synthetase 1I NM_001009680 Oas1i 0.87 (0.24) 0.018 1.83 0.13 (0.31) 1.09 −0.29 (0.22) −1.22
Immune response interferon regulatory factor 7 NM_001033691 Irf7 1.13 (0.27) 0.016 2.18 −0.05 (0.12) −1.04 0.25 (0.20) 1.19
Immune response complement component 4A
(Rodgers blood group)
NM_031504 C4a 1.18 (0.39) 0.017 2.27 0.29 (0.44) 2.27 0.05 (0.34) 1.04
Immune response hepcidin antimicrobial peptide NM_053469 Hamp 1.38 (0.74) 0.040 2.60 0.59 (0.77) 1.51 −0.56 (0.74) −1.47
Immune response myxovirus (influenza virus) resistance 2 NM_134350 Mx2 2.14 (0.95) 0.020 4.41 0.42 (0.63) 1.34 −0.72 (0.67) −1.65
Cell growth and differentiation neuronatin NM_053601 Nnat 0.99 (0.41) 0.025 1.98 0.73 (0.40) 1.66 −0.06 (0.74) −1.04
Cell growth and differentiation H19, imprinted maternally expressed
transcript
NR_027324 H19 1.16 (0.44) 0.020 2.24 0.92 (0.49) 1.89 −0.53 (0.47) −1.44
Receptors and ion channels ATPase, H+/K+ exchanging, alpha
polypeptide
NM_012509 Atp4a 0.86 (0.19) 0.017 1.81 0.45 (0.48) 1.37 −0.05 (0.59) −1.04
Receptors and ion channels sarcolipin NM_001013247 Sln 1.09 (0.61) 0.043 2.13 1.07 (0.61) 2.10 −0.23 (0.42) −1.17
Receptors and ion channels ATPase, Na+/K+ transporting, beta 4
polypeptide
NM_053381 Atp1b4 1.14 (0.63) 0.043 2.21 0.41 (0.64) 1.33 0.04 (0.81) 1.03
Others 2’-5’ oligoadenylate synthetase-like 2 NM_001009682 Oasl2 0.96 (0.34) 0.020 1.95 −0.21 (0.19) −1.15 0.08 (0.14) 1.05
Others GRAM domain containing 3 NM_001014011 Gramd3 0.97 (0.31) 0.018 1.96 −0.03 (0.41) −1.02 0.36 (0.79) 1.29
Values show gene expression. Log2 ratio reaching at least ±0.85 and p < 0.05 were considered as significant alterations
aRGD: rat genome database
bnon significant change (p > 0.05)
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Table 8 Primers to qRT-PCR
Gene name Gene symbol Acc. Number Forward Length Reverse Length
metallothionein 1a Mt1a NM_138826 caccagatctcggaatggac 20 aggagcagcagctcttcttg 20
metallothionein 2a Mt2a NM_001137564 catggaccccaactgctc 18 aggtgcatttgcattgtttg 20
cytochrome P450, family 26,
subfamily b, polypeptide 1
Cyp26b1 NM_181087 acggcaaggagatgacca 18 gcataggctgcgaagatca 19
galanin prepropeptide Gal NM_033237 tggagtttctcagtttcttgcac 23 ggtgtggtctcaggactgct 20
connector enhancer of kinase
suppressor of Ras 1
Cnksr1 NM_001039011 tgtggctgggatctgtcac 19 tgctggtggtgtgaatttct 20
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One of the major cardiovascular complications of DM is
diabetic cardiomyopathy (DCM) [40, 41], which is de-
fined as left ventricular dysfunction with hypertrophy
and fibrosis in the absence of hypertension, coronary ar-
tery disease and valvular or congenital heart disease [42].
The complex underlying molecular mechanisms of the
above-mentioned functional and morphologic changes
have been intensively investigated [40–42]. In our present
study, we have shown altered expression of several genes
related to cardiac hypertrophy and remodelling in accord-
ance with the literature (e.g. down-regulation of caspase
recruitment domain family, member 9 (Card9) [43] and
adrenoceptor alpha 1d (adra1d) [44]; up-regulation of the
angiogenesis inductor cytochrome P450, family 26, sub-
family B, polypeptide 1 (Cyp26b1) [45, 46]; FXYD do-
main containing ion transport regulator 3 (Fxyd3) also
called phospholemman-like protein potentially regulatingTable 9 qRT-PCR results
Diabetes
Description Gene symbol Acc. Number DNA MIC
fold chan
metallothionein 1a Mt1a NM_138826 2.49
metallothionein 2a Mt2a NM_001137564 3.06
cytochrome P450, family 26,
subfamily b, polypeptide 1
Cyp26b2 NM_181087 3.08
galanin/GMAP prepropeptide Gal NM_033237 5.31
connector enhancer of kinase
suppressor of Ras 1
Cnksr2 NM_001039011 2.48
Diabetes
Description Gene symbol Acc. Number DNA MIC
fold chan
metallothionein 1a Mt1a NM_138826 −2.26
metallothionein 2a Mt2a NM_001137564 −3.24
cytochrome P450, family 26,
subfamily b, polypeptide 1
Cyp26b2 NM_181087 −3.20
galanin/GMAP prepropeptide Gal NM_033237 −7.96
connector enhancer of kinase
suppressor of Ras 1
Cnksr2 NM_001039011 −3.13
MVT = preparation of minerals, vitamins, and trace elementsNa+/K+/ATP-ase activity [47–49]; ATPase, H+ Transport-
ing, Lysosomal 13 kDa, V1 Subunit G21 (Atp6v1g2) [50]
related to hepatitis C virus-associated dilated cardiomyop-
athy; and a well-known marker of hypertrophy and heart
failure, natriuretic peptide A (Nppa) [40, 41] (Tables 2
and 3). In our present study, another group of genes
altered in response to DM is involved in cell proliferation
in different organs (e.g. down-regulation of the antiprolif-
erative and tumour suppressor protocadherin-17 (Pcdh17)
[51] and up-regulation of the insulin signalling pathway
promoter connector enhancer of kinase suppressor of Ras 1
(Cnksr1) [52, 53]; and wingless-type MMTV integration
site family, member 2B (Wnt2b) playing a role in pancre-
atic beta cell replication [54] (Tables 2 and 3). These afore-
mentioned studies, in agreement with our present study,
suggest that altered metabolic parameters in DM may in-
duce cardiac gene expression changes leading to the in-
duction of general mechanisms of cell proliferation andVehicle vs. Control Vehicle
ROARRAY qRT-PCR confirmed
ge p value log2 ratio (SD) fold change regulation
0.005 2.36 (1.35) 5.13 up yes
0.003 2.36 (0.93) 5.12 up yes
0.003 2.50 (0.85) 5.65 up yes
0.018 2.69 (0.86) 6.43 up yes
0.025 0.002 (0.26) 1.00 no change no
MVT vs. Diabetes Vehicle
ROARRAY qRT-PCR confirmed
ge p value log2 ratio (SD) fold change regulation
0.017 −1,44 (0.91) −2.71 down yes
0.018 −2.53 (0.68) −5.76 down yes
0.007 −2.91 (0.32) −7.50 down yes
0.007 −2.72 (0.64) −6.60 down yes
0.004 −0.11 (0.33) 1.08 no change no
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genes have not previously been shown to play a role in the
development of diabetic cardiomyopathy. In our present
study, MVT-treatment in diabetic rats resulted in opposite
gene expression changes in case of some aforementioned
genes (e.g. caspase recruitment domain family, member 9
(Card9); adrenoceptor alpha 1d (adra1d); cytochrome
P450, family 26, subfamily B, polypeptide 1 (Cyp26b1;
FXYD domain containing ion transport regulator 3
(Fxyd3); ATPase, H+ Transporting, Lysosomal 13 kDa, V1
Subunit G21 (Atp6v1g2); etc.) showing a beneficial effect
of MVT-treatment on the development of diabetic cardio-
myopathy (Tables 2 and 5, Fig. 2). Although we have not
characterized diabetic cardiomyopathy in our present
study, STZ-treated rats are well known to develop this
cardiovascular complication at ages similar to that of used
in the present study [19].
Genes associated with increased oxidative/nitrative stress
in DM
Increased cardiovascular oxidative and nitrative stress is
another well-known factor in the development of dia-
betic cardiomyopathy [40, 41]. In the present study,
members of another functional gene cluster related to
oxidative/nitrative stress and stress response showed al-
tered expression in diabetic vehicle-treated hearts as
compared to controls, in accordance with literature data
(e.g. up-regulation of the zinc ion containing antioxida-
tive metallothionein 1a (Mt1a) and metallothionein 2a
(Mt2a) [55, 56]; the cardiovascular risk factor interleu-
kin-6 receptor (Ilr6) [57, 58]; the antioxidative heme
oxygenase (decycling) 1 (Hmox1) [59]; and glutathione S-
transferase, theta 3 (Gstt3) [60]) (Tables 2 and 3). Gluta-
thione S-transferase catalyzes the conjugation of reduced
glutathione on a wide variety of substrates [60] including
reactive oxygen and nitrogen species [61]. Interestingly,
we have found here the overexpression of glutathione S-
transferase in DM similar to the up-regulation of this
gene in metabolic syndrome [23] and cholesterol diet-
induced hyperlipidaemia [62] in our previous studies.
Our results suggest that up-regulation of antioxidative
genes including glutathione S-transferase; heme oxygen-
ase 1; metallothionein 1a and 2a may be an adaptive re-
sponse in DM to antagonize elevated oxidative/nitrative
stress in the myocardium. In contrast, decreased expres-
sion of metallothionein proteins have been reported in
the heart [63] and the aorta [64] in experimental diabetes.
Moreover, it has been published that the expression of
metallothioneins could be increased by a chelator-
regulated restoration of copper regulation [63] and zinc
supplementation in experimental diabetes [64, 65]. Never-
theless, it should be noted that these aforementioned
studies used different types of diabetes models (a genetic
T1DM model OVE26 mice and single injection of STZ inadult mice or rats) with more severe hyperglycaemia than
that developed in our model in the present study. In
addition, we have previously shown marked differences in
gene expression profiles in vascular and cardiac tissues in
response to nitrate tolerance, which indicates different
tissue-specific signalling pathways in different organs [66].
MVT-treatment in diabetic rats showed opposite gene ex-
pression changes in the cases of the aforementioned genes
(Tables 2 and 5, Fig. 2). This could be explained by the
beneficial effect of MVT-treatment on the severity of DM
and potentially reduced oxidative/nitrative stress.Genes associated with insulin resistance
Insulin resistance is another well-known phenomenon in
diabetic cardiomyopathy [40, 41]. Although the precise
mechanisms by which cardiac insulin resistance developed
in DM are poorly characterized, numerous metabolic and
hormonal changes in the diabetic heart have been demon-
strated [19–22, 40, 41]. In this present study, we have
shown altered expression of several genes related to insu-
lin resistance in the hearts of diabetic rats (e.g. up-
regulation of resistin (Retn) responsible for induction of
cardiac insulin resistance in rodents and chronic inflam-
mation in humans [67] and FK506 binding protein 5
(Fkbp5) associated with decreased ligand sensitivity of the
glucocorticoid receptor [68]. Interestingly, here we have
shown up-regulation of galanin/GMAP prepropeptide
(Gal) which has trophic effects on cells and increases insu-
lin sensitivity in the diabetic heart [69]. Increased expres-
sion of galanin might be a counter-regulatory mechanism
against insulin resistance in the diabetic heart. Surpris-
ingly, a regulatory hormone of the reproductive func-
tion, inhibin 1-alpha (Inha) [70] showed significant up-
regulation in the present study. Association of this gene
with heart or DM has never been shown previously.Genes not associated with DM before
Some of the genes showing altered expression in diabetic
hearts in the present study have not yet been related to
diabetic cardiomyopathy (e.g. up-regulation of prostaglan-
din b2 synthase (brain) (Ptgds); fibroblast growth factor
(Fgf18) and down-regulation of HOP homeobox (Hopx);
neuronal regeneration related protein (Nrep); etc.). Inter-
estingly, we have found here the overexpression of brain
expressed X-linked 1 (Bex1) in DM similar to the up-
regulation of this gene in metabolic syndrome [23] in our
previous study. Some other altered genes were not classi-
fied into specific functional clusters or indicated as yet
uncharacterized, predicted genes and fragments (e.g. up-
regulation of RGD1309808 also called similar to apolipo-
protein L2 or down-regulation of uncharacterized
LOC100909684 and LOC100910110 genes), the relevance
of which should not be ignored.
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Regular consumption of MVT preparations as medical
food for diabetics is common in developed countries.
However, preclinical or clinical evaluation of such prepa-
rations is surprisingly limited in the literature [12–16].
To the best of our knowledge, none of the investigated
and significantly altered genes in this study has been re-
ported to show altered expression, either in healthy or in
diabetic hearts in response to MVT-treatment. In the
present study, 24 genes showed significant alteration in
control MVT-treated hearts as compared to control
vehicle-treated hearts (Tables 5 and 6), however, we did
not observe any phenotypic changes in this group. Out
of the 24 aforementioned genes, 18 were not signifi-
cantly altered in diabetic MVT-treated rats compared to
the diabetes vehicle-treated ones; therefore, these genes
might be associated to the beneficial effects of MVT-
treatment observed in the diabetic group. Accordingly, a
major cluster of significantly altered cardiac genes in re-
sponse to MVT treatment in control animals was associ-
ated with immune and antimicrobial response (e.g.
complement factor B (Cfb); complement component 4a
(C4a); interferon regulatory factor 7 (irf7); hepcidin anti-
microbial peptide (Hamp); myxovirus (influenza virus)
resistance 2 (Mx2); and viral RNA degradation regulators
including 2′-5′′ oligoadenylate synthetase 1A; 1B; and
1 L; as well as 2′-5′ oligoadenylate synthetase-like 2)
which is in line with the known immune system boost-
ing effect of some of the components of the MVT prep-
aration such as e.g. selenium [71].
Limitations
Our study is not without limitations. Based on our
present results one may not be able to differentiate en-
tirely between the effects of diabetes and postnatal de-
velopment due to insulin insufficiency, however, this
model may also have clinical significance in DM in the
pediatric age [72]. Furthermore, cardiac morphological
and functional parameters to verify the development of
diabetic cardiomyopathy were not investigated in this
study; however, the neonatal STZ-injected rat is a well-
characterized model of diabetes with cardiovascular
complications including hypertension and LV hyper-
trophy with decreased cardiac function at a similar age
to that used in our present study [28–34]. Although our
study does not specify which cell type (i.e. cardiomyo-
cyte, fibroblast, smooth muscle cell, etc.) may be respon-
sible for the observed alterations of cardiac gene
expression due to DM, the contribution of cardiomyo-
cytes is likely the most significant [38, 39]. Although
longer ex vivo heart perfusion was reported to alter car-
diac gene expression profile [73], it is unlikely that
10 min perfusion in our present study significantly af-
fected gene expression profile, however, it still cannot becompletely excluded that the stability of transcripts
might have been influenced differentially by the crystal-
loid buffer used during ex vivo heart perfusion.
Our results regarding altered cardiac gene expression
due to DM are based on determinations of 41012 car-
diac transcript levels. Examination of the role of corre-
sponding proteins was out of the scope of the present
study; however, mechanistic data would strengthen our
results. In addition, it is unclear whether significantly al-
tered gene expression changes are causes or conse-
quences in the development of diabetic cardiomyopathy.
Moreover, it also needs to be further investigated whether
the MVT-treatment in DM associated with opposite car-
diac gene expression changes is the cause of attenuation
of the severity of DM or a consequence of DM. Therefore,
focused future studies are necessary to perform in-depth
functional assessment of selected genes and specifically
aim to investigate the precise role of these genes in the
cardiac effects of diabetes mellitus and/or MVT-
treatment. The results of the present study do not pro-
vide evidence on the mechanism of the MVT preparation
and the different contributions of the 26 individual com-
ponents. We assume that the potential interactions of
these components and their combined effects rather than
the value of a single component could be responsible for
the effects of the MVT preparation on cardiac gene ex-
pression changes and the severity of DM; however, the ef-
fects of each component on gene expression or DM were
not investigated in the present study. Indeed, a recent re-
port [74] showing a reduction of cancer risk in humans by
a daily intake of multivitamins and minerals suggests that
the combined effect of multivitamins is more important in
the beneficial effect than any single component.
Conclusions
In summary, we have found that 12 week-old STZ-
treated rats developed DM characterized by hypergly-
caemia and impaired glucose tolerance. We have shown
that the severity of DM could be attenuated by a com-
plex MVT preparation. We have demonstrated for the
first time that MVT-treatment is associated with pro-
found modifications of the cardiac transcriptome in both
healthy and diabetic conditions. In addition, several of
the genes showing altered expression in the hearts of
diabetic rats have not been implicated in DM previously.
We conclude that DM alters the gene expression pattern
of the myocardium, which may be involved in the devel-
opment of cardiac pathologies in the state of DM and
these pathological processes may be attenuated by
MVT-treatment. Based on our exploratory results, future
preclinical and clinical studies should be carried out to
investigate the precise role of specific genes in the devel-
opment of cardiac consequences of DM and MVT-
treatment to obtain deeper mechanistic insight.
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